リアルワールドエビデンスソリューション市場:コンポーネント(サービス、異種データセット、(請求、臨床、薬局、患者)、アプリケーション(腫瘍、心臓血管、神経、免疫)、エンドユーザー(製薬、医療技術、支払者、プロバイダ)別 - 2027年までの世界予測Real World Evidence Solutions Market by Component (Services, Disparate Data Sets, (Claims, Clinical, Pharmacy, Patient), Application (Oncology, Cardiovascular, Neurology, Immunology), End User (Pharma, Medtech, Payers, Providers) - Global Forecast to 2027 RWEソリューションの世界市場は、2022年の15億米ドルから2027年には29億米ドルに達すると予測され、予測期間中のCAGRは15.2%です。老年人口の増加とそれに伴う慢性疾患の有病率の増加、およびRWEソリューションの... もっと見る
サマリーRWEソリューションの世界市場は、2022年の15億米ドルから2027年には29億米ドルに達すると予測され、予測期間中のCAGRは15.2%です。老年人口の増加とそれに伴う慢性疾患の有病率の増加、およびRWEソリューションの使用に対する規制機関からのサポートが、RWEソリューション市場の成長を促進しています。医療・介護サービスを必要とする老年人口が多いことから、多くの国で一人当たりの医療費が増加すると予想されています。EHRや人口健康管理などのソリューションは、いくつかの国で過重労働の医療提供システムの負担を軽減するために採用されています。デジタルヘルスソリューションを通じて生成される膨大な量のRWDは、臨床結果のより良い理解に役立っています。その結果、RWEソリューションの採用は世界的に増加しています。薬局データは予測期間中に最も速い成長を遂げると予想される コンポーネントに基づいて、RWEソリューション市場は、データセットとサービスに区分されます。2021年には、高度な分析やコンサルティングサービスを提供できる大量のヘルスケアデータが利用できることから、サービスセグメントがRWEソリューション市場を支配しました。データセットセグメントは、さらにバラバラのデータセットと統合されたデータセットに区分されます。異種データセットはさらに、臨床設定データ、請求データ、薬局データ、患者主導型データ、その他のデータセットに区分されます。薬学データセット分野は、薬物乱用防止への取り組みや電子処方システムの採用が進んでいることから、予測期間中に最も速い成長率を示すと予想されます。 "2021年、医薬品開発・承認がRWEソリューション市場を席巻" RWEソリューション市場は、用途に応じて、医薬品開発・承認、医療機器開発・承認、市販後調査、市場アクセスおよび償還・適用範囲の決定、臨床・規制上の意思決定に大別されます。医薬品開発・承認分野は、特に腫瘍や心血管系治療薬の分野で臨床試験の数が増加していることから、RWEソリューション市場の大半を占めています。医薬品開発・承認分野は、さらにがん、循環器、神経、免疫、その他の治療分野に細分化されます。心血管疾患分野は、CVDの有病率の上昇と心血管レジストリの発展により、予測期間中に最も速い成長率を示すと予想されます。 「製薬会社および医療機器会社は、予測期間中に最も速い成長を目撃することが期待されます。 RWEソリューション市場は、エンドユーザーに基づき、製薬・医療機器企業、ヘルスケアプロバイダー、ヘルスケアペイヤー、その他のエンドユーザーに区分されます。製薬・医療機器企業セグメントは、2027年まで最も速い成長率を示すと予想されます。製薬会社は、承認済み医薬品と医学的に認められた医薬品の代替用途の両方を記載したデータを必要としています。製薬・医療機器研究開発への投資の増加や承認件数の増加が、このセグメントにおけるRWEソリューションの利用を促進しています。さらに、HEORに関連する支払者の要求とともに、規制遵守を満たすためのRWEソリューションの利用が増加しており、これらもRWEソリューション市場の成長を支える主要な要因となっています。 "地域別では北米がRWEソリューション市場をリード" 北米は、世界のRWEソリューション市場で最大のシェアを占めています。既存プレイヤーの多くが北米に拠点を置いています。また、老年人口の増加が慢性疾患の増加に寄与しており、新薬や医療機器に対する需要が高まっていることから、臨床試験や市販後調査活動におけるエビデンス生成の需要増に対応しています。アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると予測されています。アジア太平洋地域の市場成長は、RWE研究の採用に対する政府の取り組みが増加していることに起因しています。 主な参加企業の内訳は以下のとおりです。 - 企業タイプ別: ティア1:40%、ティア2:35%、ティア3:25 - 役職別:Cレベル35%、Dレベル45%、その他20 - 地域別:北米55%、欧州20%、アジア太平洋地域15%、中南米5%、中東・アフリカ5%。 RWEソリューション市場の主要プレイヤー RWEソリューション市場で事業を展開する主なプレイヤーは、IQVIA Holdings Inc.(米国)、IBM Corporation(米国)、OPTUM Inc.(米国)、Icon Plc(アイルランド)、Synos Health Inc.(米国)、Parexel International Corporation(米国)などが挙げられます。 リサーチの対象 当レポートでは、RWEソリューション市場を分析し、コンポーネント、アプリケーション、エンドユーザー、地域に基づいた様々な市場セグメントの市場規模や今後の成長性を推定することを目的としています。また、同市場で事業を展開する主要企業の競合分析も行い、企業概要、ソリューション提供、最近の開発状況、主要な市場戦略などを掲載しています。 本レポートを購入する理由 本レポートは、既存企業だけでなく、新規参入企業や中小企業にとっても、市場の動向を把握する上で有益なものとなるでしょう。本レポートを購入された企業は、以下の戦略の1つまたは複数を組み合わせて、市場でのポジションを強化することができます。 本レポートでは、以下に関する洞察を提供しています。 市場浸透度。RWEソリューション市場におけるトッププレイヤーのソリューションポートフォリオに関する包括的な情報。本レポートでは、コンポーネント、アプリケーション、エンドユーザー、地域別に同市場を分析しています。 市場の発展。コンポーネント、アプリケーション、エンドユーザー、地域ごとに、有望な新興市場に関する包括的な情報を提供します。 市場の多様化。RWEソリューション市場におけるソリューションポートフォリオ、成長地域、最近の開発、投資に関する詳細な情報 競争力のある評価。RWEソリューション市場における主要プレイヤーの市場ランキング、成長戦略、ソリューション提供、能力に関する詳細な評価 目次1 INTRODUCTION 231.1 OBJECTIVES OF THE STUDY 23 1.2 MARKET DEFINITION 23 1.2.1 INCLUSIONS AND EXCLUSIONS 24 1.2.2 MARKETS COVERED 25 1.2.3 YEARS CONSIDERED FOR THE STUDY 25 1.3 CURRENCY 26 TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 26 1.4 LIMITATIONS 26 1.5 STAKEHOLDERS 26 1.6 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH DATA 28 FIGURE 1 RESEARCH DESIGN 28 2.1.1 SECONDARY DATA 28 2.1.1.1 Key data from secondary sources 29 2.1.2 PRIMARY DATA 30 FIGURE 2 PRIMARY SOURCES 30 2.1.2.1 Key data from primary sources 31 2.1.2.2 Insights from primary experts 32 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 32 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 33 2.2 MARKET SIZE ESTIMATION: RWE SOLUTIONS MARKET 33 FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 34 FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL EXTRAPOLATION 35 FIGURE 7 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 36 FIGURE 8 CAGR PROJECTIONS: OVERALL RWE SOLUTIONS MARKET 36 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 38 FIGURE 9 DATA TRIANGULATION METHODOLOGY 38 2.4 MARKET RANKING ANALYSIS 39 2.5 ASSUMPTIONS FOR THE STUDY 39 2.6 RISK ASSESSMENT 39 TABLE 2 RISK ASSESSMENT: RWE SOLUTIONS MARKET 39 2.7 LIMITATIONS 40 2.7.1 METHODOLOGY-RELATED LIMITATIONS 40 3 EXECUTIVE SUMMARY 41 FIGURE 10 RWE SOLUTIONS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION) 41 FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42 FIGURE 12 DISPARATE DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42 FIGURE 13 RWE SOLUTIONS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 43 FIGURE 14 RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 43 FIGURE 15 RWE SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 44 FIGURE 16 RWE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 45 4 PREMIUM INSIGHTS 46 4.1 RWE SOLUTIONS MARKET OVERVIEW 46 FIGURE 17 SUPPORT FROM REGULATORY BODIES FOR THE USE OF RWE SOLUTIONS IS A MAJOR FACTOR DRIVING THE MARKET GROWTH 46 4.2 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER AND COUNTRY (2021) 47 FIGURE 18 JAPAN ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 47 4.3 RWE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48 FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 48 4.4 REGIONAL MIX: RWE SOLUTIONS MARKET (2022−2027) 49 FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RWE SOLUTIONS MARKET DURING THE FORECAST PERIOD 49 4.5 RWE SOLUTIONS MARKET: DEVELOPED VS. EMERGING MARKETS 49 FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 49 5 MARKET OVERVIEW 50 5.1 INTRODUCTION 50 5.2 MARKET DYNAMICS 50 FIGURE 22 RWE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 TABLE 3 MARKET DYNAMICS: IMPACT ANALYSIS 51 5.2.1 DRIVERS 51 5.2.1.1 Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases 51 5.2.1.2 Shift from volume- to value-based care 52 5.2.1.3 Potential of RWE in reducing drug development costs and expediting the drug development process 53 5.2.1.4 Increased R&D spending for the development of new pharmaceutical products and medical devices 53 FIGURE 23 NUMBER OF CLINICAL TRIALS STARTED DURING 2015–2020 54 5.2.1.5 Support from regulatory bodies for the use of RWE solutions 54 5.2.2 RESTRAINTS 55 5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies 55 5.2.3 OPPORTUNITIES 55 5.2.3.1 Growth opportunities in emerging markets 55 5.2.3.2 Rise in focus on end-to-end RWE services 57 5.2.4 CHALLENGES 57 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure 57 5.2.4.2 Shortage of skilled professionals 57 6 INDUSTRY INSIGHTS 59 6.1 INDUSTRY TRENDS 59 6.1.1 EMERGING ROLE OF WEARABLE DEVICES 59 FIGURE 24 UTILIZATION OF WEARABLES IN CLINICAL TRIALS, BY THERAPEUTIC AREA, 2019 59 6.1.2 SOCIAL MEDIA-SOURCED RWE 60 6.1.3 RISE IN THE USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY 61 FIGURE 25 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE 61 6.1.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62 FIGURE 26 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62 6.1.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT 62 6.2 REAL-WORLD DATA SOURCES 63 TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 63 6.3 ECOSYSTEM ANALYSIS 64 FIGURE 27 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS) 65 FIGURE 28 ECOSYSTEM COVERAGE: RWE SOLUTIONS MARKET 65 6.4 PORTER’S FIVE FORCES ANALYSIS 66 TABLE 5 PORTER’S FIVE FORCES ANALYSIS 66 6.4.1 THREAT OF NEW ENTRANTS 66 6.4.2 BARGAINING POWER OF SUPPLIERS 66 6.4.3 BARGAINING POWER OF BUYERS 66 6.4.4 THREAT OF SUBSTITUTES 67 6.4.5 INTENSITY OF COMPETITIVE RIVALRY 67 6.5 PRICING ANALYSIS 67 6.5.1 AVERAGE SELLING PRICE 67 6.5.2 HCIT EXPENDITURE/PRICING ANALYSIS 68 6.5.2.1 North America 68 TABLE 6 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY 68 6.5.2.2 Europe 68 6.5.2.3 Asia Pacific 69 TABLE 7 JAPAN: HEALTHCARE IT INITIATIVES AND FUNDING 69 6.6 TECHNOLOGY ANALYSIS 70 6.7 REGULATORY BODIES, GOVERNMENTS, AND OTHER ORGANIZATIONS 70 6.7.1 NORTH AMERICA 70 6.7.1.1 Case examples 72 6.7.2 EUROPE 73 6.7.3 ASIA PACIFIC 74 6.7.3.1 China 74 6.7.3.2 Japan 74 6.8 PATENT ANALYSIS 75 6.8.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS 75 FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 2016–2021 75 6.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75 FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR MEDICAL SIMULATION PATENTS (JANUARY 2011 TO JUNE 2021) 76 6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE RWE SOLUTIONS MARKET 76 FIGURE 31 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR RWE SOLUTIONS, 2016–2021 76 TABLE 8 LIST OF PATENTS IN THE RWE SOLUTIONS MARKET, 2019–2022 77 6.9 KEY CONFERENCES AND EVENTS (2022-2023) 78 TABLE 9 RWE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 78 6.10 KEY STAKEHOLDERS AND BUYING CRITERIA 79 6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS 79 TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS 80 6.10.2 BUYING CRITERIA 80 FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 80 TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS 80 7 RWE SOLUTIONS MARKET, BY COMPONENT 81 7.1 INTRODUCTION 82 TABLE 12 RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 82 7.2 SERVICES 82 7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND 82 TABLE 13 RWE SERVICES OFFERED BY KEY MARKET PLAYERS 83 TABLE 14 RWE SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83 7.3 DATA SETS 84 TABLE 15 DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 84 TABLE 16 DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85 7.3.1 DISPARATE DATA SETS 85 TABLE 17 DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86 TABLE 18 DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86 7.3.1.1 Clinical settings data set 87 7.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth 87 FIGURE 34 ADOPTION OF EHR BY HOSPITAL SERVICE TYPE, 2019-2021 87 TABLE 19 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS 88 TABLE 20 CLINICAL SETTINGS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88 7.3.1.2 Claims data set 89 7.3.1.2.1 Growing need to understand the economic benefits of drug reimbursement by payers to drive growth 89 TABLE 21 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS 89 TABLE 22 CLAIMS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90 7.3.1.3 Pharmacy data set 90 7.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth 90 FIGURE 35 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN THE US (2018-2021) 91 TABLE 23 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS 91 TABLE 24 PHARMACY DISPARATE DATA SET MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92 7.3.1.4 Patient-powered data set 92 7.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth 92 TABLE 25 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS 93 TABLE 26 RWE PATIENT-POWERED DISPARATE DATA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93 7.3.1.5 Registry-based data sets 94 7.3.1.5.1 Increasing number of disease registries is driving the demand for registry-based data sets in evidence generation 94 TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION 94 TABLE 28 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS 95 TABLE 29 REGISTRY-BASED DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95 7.3.2 INTEGRATED DATA SETS 96 7.3.2.1 Increasing demand for integrated data from multiple sources to drive growth 96 TABLE 30 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS 96 TABLE 31 INTEGRATED DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97 8 RWE SOLUTIONS MARKET, BY APPLICATION 98 8.1 INTRODUCTION 99 FIGURE 36 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022 99 TABLE 32 RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99 8.2 DRUG DEVELOPMENT AND APPROVALS 100 TABLE 33 RWE SOLUTIONS MARKET IN DRUG DEVELOPMENT AND APPROVALS, BY TYPE 2020–2027 (USD MILLION) 100 8.2.1 ONCOLOGY 100 8.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth 100 TABLE 34 LIST OF PIPELINE DRUGS FOR ONCOLOGY (2018) 101 TABLE 35 DRUG DEVELOPMENT AND APPROVALS MARKET IN ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 102 8.2.2 CARDIOVASCULAR DISEASE 102 8.2.2.1 High prevalence of CVD to drive growth 102 TABLE 36 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASE (BY FEBRUARY 2022) 103 TABLE 37 DRUG DEVELOPMENT AND APPROVALS MARKET IN CARDIOVASCULAR DISEASE, BY COUNTRY, 2020–2027 (USD MILLION) 104 8.2.3 NEUROLOGY 104 8.2.3.1 Growing prevalence of neurological disorders to drive growth 104 TABLE 38 DRUG DEVELOPMENT AND APPROVALS MARKET IN NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 105 8.2.4 IMMUNOLOGY 105 8.2.4.1 Increasing focus on developing innovative products to drive growth 105 TABLE 39 DRUG DEVELOPMENT AND APPROVALS MARKET IN IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 106 8.2.5 OTHER THERAPEUTIC AREAS 106 TABLE 40 DRUG DEVELOPMENT AND APPROVALS MARKET IN OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 107 8.3 MEDICAL DEVICE DEVELOPMENT AND APPROVALS 107 8.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND 107 TABLE 41 RWE SOLUTIONS MARKET IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS, BY COUNTRY, 2020–2027 (USD MILLION) 108 8.4 POST-MARKET SURVEILLANCE 109 8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE 109 TABLE 42 RWE SOLUTIONS MARKET IN POST-MARKET SURVEILLANCE, BY COUNTRY, 2020–2027 (USD MILLION) 110 8.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING 110 8.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS 110 TABLE 43 RWE SOLUTIONS MARKET IN MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING, BY COUNTRY, 2020–2027 (USD MILLION) 111 8.6 CLINICAL AND REGULATORY DECISION MAKING 111 8.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS DRIVING THE USE OF RWE SOLUTIONS IN THE SEGMENT 111 TABLE 44 RWE SOLUTIONS MARKET IN CLINICAL AND REGULATORY DECISION MAKING, BY COUNTRY, 2020–2027 (USD MILLION) 112 9 RWE SOLUTIONS MARKET, BY END USER 113 9.1 INTRODUCTION 114 TABLE 45 RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 114 9.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES 114 9.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH 114 FIGURE 37 FDA PHASE TRANSITION SUCCESS RATES, 2011–2020 115 FIGURE 38 ANNUAL DRUG APPROVALS BY CDER (FDA), 2011–2021 116 FIGURE 39 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2011–2020 116 TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117 9.3 HEALTHCARE PAYERS 117 9.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND 117 TABLE 47 RWE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2020–2027 (USD MILLION) 118 9.4 HEALTHCARE PROVIDERS 119 9.4.1 RISE IN THE NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE PROVIDERS TO BOOST USE 119 TABLE 48 RWE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2020–2027 (USD MILLION) 120 9.5 OTHER END USERS 120 TABLE 49 RWE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 121 10 RWE SOLUTIONS MARKET, BY REGION 122 10.1 INTRODUCTION 123 TABLE 50 RWE SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 123 10.2 NORTH AMERICA 123 FIGURE 40 NORTH AMERICA: RWE SOLUTIONS MARKET SNAPSHOT 124 TABLE 51 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124 TABLE 52 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 125 TABLE 53 NORTH AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125 TABLE 54 NORTH AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125 TABLE 55 NORTH AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126 TABLE 56 NORTH AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 126 TABLE 57 NORTH AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 127 10.2.1 US 127 10.2.1.1 The US accounted for the largest share of the North American market 127 TABLE 58 US: MACROECONOMIC INDICATORS 128 TABLE 59 US: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 128 TABLE 60 US: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 128 TABLE 61 US: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 129 TABLE 62 US: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129 TABLE 63 US: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130 TABLE 64 US: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 130 10.2.2 CANADA 130 10.2.2.1 Growing number of clinical trials in Canada to drive market growth 130 TABLE 65 CANADA: MACROECONOMIC INDICATORS 131 TABLE 66 CANADA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 131 TABLE 67 CANADA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132 TABLE 68 CANADA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132 TABLE 69 CANADA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 132 TABLE 70 CANADA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 133 TABLE 71 CANADA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 133 10.3 EUROPE 133 TABLE 72 EUROPE: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134 TABLE 73 EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 135 TABLE 74 EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135 TABLE 75 EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135 TABLE 76 EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136 TABLE 77 EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 136 TABLE 78 EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 137 10.3.1 GERMANY 137 10.3.1.1 High pharmaceutical R&D spending in Germany to boost the market growth 137 TABLE 79 GERMANY: MACROECONOMIC INDICATORS 138 TABLE 80 GERMANY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 138 TABLE 81 GERMANY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139 TABLE 82 GERMANY: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139 TABLE 83 GERMANY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 140 TABLE 84 GERMANY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 140 TABLE 85 GERMANY: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 141 10.3.2 UK 141 10.3.2.1 The growing adoption of HTA in the UK supports market growth 141 TABLE 86 UK: MACROECONOMIC INDICATORS 142 TABLE 87 UK: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 142 TABLE 88 UK: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 142 TABLE 89 UK: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 143 TABLE 90 UK: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143 TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 144 TABLE 92 UK: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 144 10.3.3 FRANCE 144 10.3.3.1 High number of oncology clinical trials in France to drive market growth 144 TABLE 93 FRANCE: MACROECONOMIC INDICATORS 145 TABLE 94 FRANCE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 145 TABLE 95 FRANCE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146 TABLE 96 FRANCE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146 TABLE 97 FRANCE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 146 TABLE 98 FRANCE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147 TABLE 99 FRANCE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 147 10.3.4 ITALY 147 10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes 147 TABLE 100 ITALY: MACROECONOMIC INDICATORS 148 TABLE 101 ITALY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 149 TABLE 102 ITALY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149 TABLE 103 ITALY: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149 TABLE 104 ITALY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150 TABLE 105 ITALY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 150 TABLE 106 ITALY: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 151 10.3.5 SPAIN 151 10.3.5.1 Rising R&D expenditure to propel market growth in Spain 151 TABLE 107 SPAIN: MACROECONOMIC INDICATORS 152 TABLE 108 SPAIN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 152 TABLE 109 SPAIN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152 TABLE 110 SPAIN: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 153 TABLE 111 SPAIN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153 TABLE 112 SPAIN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154 TABLE 113 SPAIN: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 154 10.3.6 REST OF EUROPE 154 TABLE 114 REST OF EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 155 TABLE 115 REST OF EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 155 TABLE 116 REST OF EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 156 TABLE 117 REST OF EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 156 TABLE 118 REST OF EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 157 TABLE 119 REST OF EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 157 10.4 ASIA PACIFIC 158 FIGURE 41 ASIA PACIFIC: RWE SOLUTIONS MARKET SNAPSHOT 158 TABLE 120 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159 TABLE 121 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 159 TABLE 122 ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 159 TABLE 123 ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 160 TABLE 124 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160 TABLE 125 ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161 TABLE 126 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 161 10.4.1 JAPAN 161 10.4.1.1 Stringent regulatory scenario in Japan to restrain market growth 161 TABLE 127 JAPAN: MACROECONOMIC INDICATORS 162 TABLE 128 JAPAN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 163 TABLE 129 JAPAN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163 TABLE 130 JAPAN: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163 TABLE 131 JAPAN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 164 TABLE 132 JAPAN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164 TABLE 133 JAPAN: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 165 10.4.2 CHINA 165 10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth 165 TABLE 134 CHINA: MACROECONOMIC INDICATORS 166 TABLE 135 CHINA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 166 TABLE 136 CHINA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167 TABLE 137 CHINA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167 TABLE 138 CHINA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 167 TABLE 139 CHINA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168 TABLE 140 CHINA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 168 10.4.3 INDIA 168 10.4.3.1 Growing adoption of outcomes-based research among pharmaceutical and medical device manufacturers in India to drive market growth 168 TABLE 141 INDIA: MACROECONOMIC INDICATORS 169 TABLE 142 INDIA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 169 TABLE 143 INDIA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170 TABLE 144 INDIA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170 TABLE 145 INDIA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 170 TABLE 146 INDIA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171 TABLE 147 INDIA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 171 10.4.4 REST OF ASIA PACIFIC 171 TABLE 148 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 172 TABLE 149 REST OF ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172 TABLE 150 REST OF ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 173 TABLE 151 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 173 TABLE 152 REST OF ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 174 TABLE 153 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 174 10.5 LATIN AMERICA 174 10.5.1 INCREASED HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 174 TABLE 154 LATIN AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 175 TABLE 155 LATIN AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 175 TABLE 156 LATIN AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176 TABLE 157 LATIN AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176 TABLE 158 LATIN AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 177 TABLE 159 LATIN AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 177 10.6 MIDDLE EAST & AFRICA 177 10.6.1 GROWING AVAILABILITY OF HEALTHCARE FUNDING IN THE MIDDLE EAST OFFERS OPPORTUNITIES FOR MARKET GROWTH 177 TABLE 160 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 178 TABLE 161 MIDDLES EAST & AFRICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 178 TABLE 162 MIDDLES EAST & AFRICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 179 TABLE 163 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 179 TABLE 164 MIDDLES EAST & AFRICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180 TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 180 11 COMPETITIVE LANDSCAPE 181 11.1 OVERVIEW 181 11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN 181 TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE RWE SOLUTIONS MARKET 182 11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 184 FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN THE RWE SOLUTIONS MARKET 184 11.4 MARKET RANKING ANALYSIS 185 FIGURE 43 RWE SOLUTIONS MARKET RANKING, BY KEY PLAYER, 2021 185 11.5 COMPETITIVE BENCHMARKING 186 TABLE 167 RWE SOLUTIONS MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS 186 11.6 COMPANY FOOTPRINT 187 11.6.1 END-USER FOOTPRINT OF COMPANIES 187 11.6.2 PRODUCT FOOTPRINT OF COMPANIES 188 11.6.3 REGIONAL FOOTPRINT OF COMPANIES 189 11.7 COMPANY EVALUATION QUADRANT 190 11.7.1 STARS 191 11.7.2 EMERGING LEADERS 191 11.7.3 PERVASIVE PLAYERS 191 11.7.4 PARTICIPANTS 191 FIGURE 44 RWE SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021) 192 11.8 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 192 11.8.1 PROGRESSIVE COMPANIES 192 11.8.2 STARTING BLOCKS 193 11.8.3 RESPONSIVE COMPANIES 193 11.8.4 DYNAMIC COMPANIES 193 FIGURE 45 START-UP/SME EVALUATION QUADRANT (2021) 194 11.9 COMPETITIVE SCENARIO 194 11.9.1 FDA APPROVALS/SERVICE ENHANCEMENTS 194 TABLE 168 FDA APPROVALS/ENHANCEMENTS, 2019–2022 195 11.9.2 DEALS 195 TABLE 169 DEALS, 2019–2022 195 11.9.3 OTHER DEVELOPMENTS 197 TABLE 170 OTHER DEVELOPMENTS, 2019–2022 197 12 COMPANY PROFILES 198 12.1 KEY PLAYERS 198 (Business Overview, Products, Recent Developments, MnM View)* 12.1.1 IQVIA HOLDINGS INC. 198 TABLE 171 IQVIA HOLDINGS INC.: BUSINESS OVERVIEW 198 FIGURE 46 IQVIA HOLDINGS INC: COMPANY SNAPSHOT (2021) 199 12.1.2 IBM CORPORATION (IBM) 202 TABLE 172 IBM CORPORATION: BUSINESS OVERVIEW 202 FIGURE 47 IBM CORPORATION: COMPANY SNAPSHOT (2021) 203 12.1.3 OPTUM INC. (A SUBSIDIARY OF THE UNITED HEALTH GROUP, INC.) 205 TABLE 173 OPTUM INC.: BUSINESS OVERVIEW 205 FIGURE 48 OPTUM INC.: COMPANY SNAPSHOT (2021) 206 12.1.4 ICON PLC. 208 TABLE 174 ICON PLC.: BUSINESS OVERVIEW 208 FIGURE 49 ICON PLC.: COMPANY SNAPSHOT (2021) 209 12.1.5 SYNEOS HEALTH, INC. 211 TABLE 175 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 211 FIGURE 50 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021) 212 12.1.6 PAREXEL INTERNATIONAL CORPORATION 214 TABLE 176 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 214 12.1.7 THERMO FISHER SCIENTIFIC INC. 216 TABLE 177 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 216 FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 217 12.1.8 LABCORP HOLDINGS 219 TABLE 178 LABCORP HOLDINGS: BUSINESS OVERVIEW 219 FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021) 220 12.1.9 ORACLE CORPORATION 222 TABLE 179 ORACLE CORPORATION: BUSINESS OVERVIEW 222 FIGURE 53 ORACLE CORPORATION: COMPANY SNAPSHOT (2021) 223 12.1.10 ELEVANCE HEALTH 225 TABLE 180 ELEVANCE HEALTH: BUSINESS OVERVIEW 225 FIGURE 54 ELEVANCE HEALTH: COMPANY SNAPSHOT (2021) 226 12.1.11 SAS INSTITUTE 228 TABLE 181 SAS INSTITUTE: BUSINESS OVERVIEW 228 FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2021) 229 12.1.12 AETION INC. 231 TABLE 182 AETION INC.: BUSINESS OVERVIEW 231 12.1.13 TRINETX LLC 234 TABLE 183 TRINETX LLC: BUSINESS OVERVIEW 234 12.1.14 TRINITY LIFE SCIENCES 237 TABLE 184 TRINITY LIFE SCIENCES: BUSINESS OVERVIEW 237 12.1.15 PERKINELMER INC. 239 TABLE 185 PERKINELMER INC.: BUSINESS OVERVIEW 239 FIGURE 56 PERKINELMER INC.: COMPANY SNAPSHOT (2021) 240 12.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION 242 TABLE 186 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: BUSINESS OVERVIEW 242 FIGURE 57 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2021) 243 12.1.17 CLINIGEN 245 TABLE 187 CLINIGEN: BUSINESS OVERVIEW 245 FIGURE 58 CLINIGEN: COMPANY SNAPSHOT (2021) 245 12.1.18 CEGEDIM HEALTH DATA 247 TABLE 188 CEGEDIM HEALTH DATA: BUSINESS OVERVIEW 247 FIGURE 59 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2021) 247 12.1.19 VERANTOS INC. 249 TABLE 189 VERANTOS INC.: BUSINESS OVERVIEW 249 12.1.20 MEDPACE HOLDINGS INC. 251 TABLE 190 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 251 FIGURE 60 MEDPCE HOLDINGS INC.: COMPANY SNAPSHOT (2021) 252 *Details on Business Overview, Products, Recent Developments, MnM View might not be captured in case of unlisted companies. 12.2 OTHER PLAYERS 254 12.2.1 HEALTHVERITY INC. 254 12.2.2 DATAVANT 254 12.2.3 SYAPSE INC. 255 12.2.4 TEMPUS LABS INC. 255 12.2.5 FLATIRON HEALTH 256 13 APPENDIX 257 13.1 DISCUSSION GUIDE 257 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262 13.3 CUSTOMIZATION OPTIONS 264 13.4 RELATED REPORTS 264 13.5 AUTHOR DETAILS 265
SummaryThe global RWE Solutions market is projected to reach USD 2.9 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 15.2% during the forecast period. Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases and support from regulatory bodies for the use of RWE solutions is driving the growth of the RWE solutions market. Given the large pool of geriatric individuals requiring health and long-term care services, the healthcare cost per person is expected to increase in many countries. Solutions such as EHR and population health management are being employed to reduce the burden on the overworked healthcare delivery systems in several countries. The significant amount of RWD that is being generated through digital health solutions is helping in better understanding clinical outcomes. As a result, the adoption of RWE solutions is increasing globally. Table of Contents1 INTRODUCTION 231.1 OBJECTIVES OF THE STUDY 23 1.2 MARKET DEFINITION 23 1.2.1 INCLUSIONS AND EXCLUSIONS 24 1.2.2 MARKETS COVERED 25 1.2.3 YEARS CONSIDERED FOR THE STUDY 25 1.3 CURRENCY 26 TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 26 1.4 LIMITATIONS 26 1.5 STAKEHOLDERS 26 1.6 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH DATA 28 FIGURE 1 RESEARCH DESIGN 28 2.1.1 SECONDARY DATA 28 2.1.1.1 Key data from secondary sources 29 2.1.2 PRIMARY DATA 30 FIGURE 2 PRIMARY SOURCES 30 2.1.2.1 Key data from primary sources 31 2.1.2.2 Insights from primary experts 32 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 32 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 33 2.2 MARKET SIZE ESTIMATION: RWE SOLUTIONS MARKET 33 FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 34 FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL EXTRAPOLATION 35 FIGURE 7 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 36 FIGURE 8 CAGR PROJECTIONS: OVERALL RWE SOLUTIONS MARKET 36 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 38 FIGURE 9 DATA TRIANGULATION METHODOLOGY 38 2.4 MARKET RANKING ANALYSIS 39 2.5 ASSUMPTIONS FOR THE STUDY 39 2.6 RISK ASSESSMENT 39 TABLE 2 RISK ASSESSMENT: RWE SOLUTIONS MARKET 39 2.7 LIMITATIONS 40 2.7.1 METHODOLOGY-RELATED LIMITATIONS 40 3 EXECUTIVE SUMMARY 41 FIGURE 10 RWE SOLUTIONS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION) 41 FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42 FIGURE 12 DISPARATE DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42 FIGURE 13 RWE SOLUTIONS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 43 FIGURE 14 RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 43 FIGURE 15 RWE SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 44 FIGURE 16 RWE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 45 4 PREMIUM INSIGHTS 46 4.1 RWE SOLUTIONS MARKET OVERVIEW 46 FIGURE 17 SUPPORT FROM REGULATORY BODIES FOR THE USE OF RWE SOLUTIONS IS A MAJOR FACTOR DRIVING THE MARKET GROWTH 46 4.2 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER AND COUNTRY (2021) 47 FIGURE 18 JAPAN ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 47 4.3 RWE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48 FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 48 4.4 REGIONAL MIX: RWE SOLUTIONS MARKET (2022−2027) 49 FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RWE SOLUTIONS MARKET DURING THE FORECAST PERIOD 49 4.5 RWE SOLUTIONS MARKET: DEVELOPED VS. EMERGING MARKETS 49 FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 49 5 MARKET OVERVIEW 50 5.1 INTRODUCTION 50 5.2 MARKET DYNAMICS 50 FIGURE 22 RWE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 TABLE 3 MARKET DYNAMICS: IMPACT ANALYSIS 51 5.2.1 DRIVERS 51 5.2.1.1 Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases 51 5.2.1.2 Shift from volume- to value-based care 52 5.2.1.3 Potential of RWE in reducing drug development costs and expediting the drug development process 53 5.2.1.4 Increased R&D spending for the development of new pharmaceutical products and medical devices 53 FIGURE 23 NUMBER OF CLINICAL TRIALS STARTED DURING 2015–2020 54 5.2.1.5 Support from regulatory bodies for the use of RWE solutions 54 5.2.2 RESTRAINTS 55 5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies 55 5.2.3 OPPORTUNITIES 55 5.2.3.1 Growth opportunities in emerging markets 55 5.2.3.2 Rise in focus on end-to-end RWE services 57 5.2.4 CHALLENGES 57 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure 57 5.2.4.2 Shortage of skilled professionals 57 6 INDUSTRY INSIGHTS 59 6.1 INDUSTRY TRENDS 59 6.1.1 EMERGING ROLE OF WEARABLE DEVICES 59 FIGURE 24 UTILIZATION OF WEARABLES IN CLINICAL TRIALS, BY THERAPEUTIC AREA, 2019 59 6.1.2 SOCIAL MEDIA-SOURCED RWE 60 6.1.3 RISE IN THE USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY 61 FIGURE 25 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE 61 6.1.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62 FIGURE 26 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62 6.1.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT 62 6.2 REAL-WORLD DATA SOURCES 63 TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 63 6.3 ECOSYSTEM ANALYSIS 64 FIGURE 27 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS) 65 FIGURE 28 ECOSYSTEM COVERAGE: RWE SOLUTIONS MARKET 65 6.4 PORTER’S FIVE FORCES ANALYSIS 66 TABLE 5 PORTER’S FIVE FORCES ANALYSIS 66 6.4.1 THREAT OF NEW ENTRANTS 66 6.4.2 BARGAINING POWER OF SUPPLIERS 66 6.4.3 BARGAINING POWER OF BUYERS 66 6.4.4 THREAT OF SUBSTITUTES 67 6.4.5 INTENSITY OF COMPETITIVE RIVALRY 67 6.5 PRICING ANALYSIS 67 6.5.1 AVERAGE SELLING PRICE 67 6.5.2 HCIT EXPENDITURE/PRICING ANALYSIS 68 6.5.2.1 North America 68 TABLE 6 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY 68 6.5.2.2 Europe 68 6.5.2.3 Asia Pacific 69 TABLE 7 JAPAN: HEALTHCARE IT INITIATIVES AND FUNDING 69 6.6 TECHNOLOGY ANALYSIS 70 6.7 REGULATORY BODIES, GOVERNMENTS, AND OTHER ORGANIZATIONS 70 6.7.1 NORTH AMERICA 70 6.7.1.1 Case examples 72 6.7.2 EUROPE 73 6.7.3 ASIA PACIFIC 74 6.7.3.1 China 74 6.7.3.2 Japan 74 6.8 PATENT ANALYSIS 75 6.8.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS 75 FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 2016–2021 75 6.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75 FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR MEDICAL SIMULATION PATENTS (JANUARY 2011 TO JUNE 2021) 76 6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE RWE SOLUTIONS MARKET 76 FIGURE 31 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR RWE SOLUTIONS, 2016–2021 76 TABLE 8 LIST OF PATENTS IN THE RWE SOLUTIONS MARKET, 2019–2022 77 6.9 KEY CONFERENCES AND EVENTS (2022-2023) 78 TABLE 9 RWE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 78 6.10 KEY STAKEHOLDERS AND BUYING CRITERIA 79 6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS 79 TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS 80 6.10.2 BUYING CRITERIA 80 FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 80 TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS 80 7 RWE SOLUTIONS MARKET, BY COMPONENT 81 7.1 INTRODUCTION 82 TABLE 12 RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 82 7.2 SERVICES 82 7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND 82 TABLE 13 RWE SERVICES OFFERED BY KEY MARKET PLAYERS 83 TABLE 14 RWE SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83 7.3 DATA SETS 84 TABLE 15 DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 84 TABLE 16 DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85 7.3.1 DISPARATE DATA SETS 85 TABLE 17 DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86 TABLE 18 DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86 7.3.1.1 Clinical settings data set 87 7.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth 87 FIGURE 34 ADOPTION OF EHR BY HOSPITAL SERVICE TYPE, 2019-2021 87 TABLE 19 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS 88 TABLE 20 CLINICAL SETTINGS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88 7.3.1.2 Claims data set 89 7.3.1.2.1 Growing need to understand the economic benefits of drug reimbursement by payers to drive growth 89 TABLE 21 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS 89 TABLE 22 CLAIMS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90 7.3.1.3 Pharmacy data set 90 7.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth 90 FIGURE 35 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN THE US (2018-2021) 91 TABLE 23 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS 91 TABLE 24 PHARMACY DISPARATE DATA SET MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92 7.3.1.4 Patient-powered data set 92 7.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth 92 TABLE 25 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS 93 TABLE 26 RWE PATIENT-POWERED DISPARATE DATA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93 7.3.1.5 Registry-based data sets 94 7.3.1.5.1 Increasing number of disease registries is driving the demand for registry-based data sets in evidence generation 94 TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION 94 TABLE 28 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS 95 TABLE 29 REGISTRY-BASED DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95 7.3.2 INTEGRATED DATA SETS 96 7.3.2.1 Increasing demand for integrated data from multiple sources to drive growth 96 TABLE 30 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS 96 TABLE 31 INTEGRATED DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97 8 RWE SOLUTIONS MARKET, BY APPLICATION 98 8.1 INTRODUCTION 99 FIGURE 36 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022 99 TABLE 32 RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99 8.2 DRUG DEVELOPMENT AND APPROVALS 100 TABLE 33 RWE SOLUTIONS MARKET IN DRUG DEVELOPMENT AND APPROVALS, BY TYPE 2020–2027 (USD MILLION) 100 8.2.1 ONCOLOGY 100 8.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth 100 TABLE 34 LIST OF PIPELINE DRUGS FOR ONCOLOGY (2018) 101 TABLE 35 DRUG DEVELOPMENT AND APPROVALS MARKET IN ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 102 8.2.2 CARDIOVASCULAR DISEASE 102 8.2.2.1 High prevalence of CVD to drive growth 102 TABLE 36 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASE (BY FEBRUARY 2022) 103 TABLE 37 DRUG DEVELOPMENT AND APPROVALS MARKET IN CARDIOVASCULAR DISEASE, BY COUNTRY, 2020–2027 (USD MILLION) 104 8.2.3 NEUROLOGY 104 8.2.3.1 Growing prevalence of neurological disorders to drive growth 104 TABLE 38 DRUG DEVELOPMENT AND APPROVALS MARKET IN NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 105 8.2.4 IMMUNOLOGY 105 8.2.4.1 Increasing focus on developing innovative products to drive growth 105 TABLE 39 DRUG DEVELOPMENT AND APPROVALS MARKET IN IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 106 8.2.5 OTHER THERAPEUTIC AREAS 106 TABLE 40 DRUG DEVELOPMENT AND APPROVALS MARKET IN OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 107 8.3 MEDICAL DEVICE DEVELOPMENT AND APPROVALS 107 8.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND 107 TABLE 41 RWE SOLUTIONS MARKET IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS, BY COUNTRY, 2020–2027 (USD MILLION) 108 8.4 POST-MARKET SURVEILLANCE 109 8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE 109 TABLE 42 RWE SOLUTIONS MARKET IN POST-MARKET SURVEILLANCE, BY COUNTRY, 2020–2027 (USD MILLION) 110 8.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING 110 8.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS 110 TABLE 43 RWE SOLUTIONS MARKET IN MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING, BY COUNTRY, 2020–2027 (USD MILLION) 111 8.6 CLINICAL AND REGULATORY DECISION MAKING 111 8.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS DRIVING THE USE OF RWE SOLUTIONS IN THE SEGMENT 111 TABLE 44 RWE SOLUTIONS MARKET IN CLINICAL AND REGULATORY DECISION MAKING, BY COUNTRY, 2020–2027 (USD MILLION) 112 9 RWE SOLUTIONS MARKET, BY END USER 113 9.1 INTRODUCTION 114 TABLE 45 RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 114 9.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES 114 9.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH 114 FIGURE 37 FDA PHASE TRANSITION SUCCESS RATES, 2011–2020 115 FIGURE 38 ANNUAL DRUG APPROVALS BY CDER (FDA), 2011–2021 116 FIGURE 39 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2011–2020 116 TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117 9.3 HEALTHCARE PAYERS 117 9.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND 117 TABLE 47 RWE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2020–2027 (USD MILLION) 118 9.4 HEALTHCARE PROVIDERS 119 9.4.1 RISE IN THE NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE PROVIDERS TO BOOST USE 119 TABLE 48 RWE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2020–2027 (USD MILLION) 120 9.5 OTHER END USERS 120 TABLE 49 RWE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 121 10 RWE SOLUTIONS MARKET, BY REGION 122 10.1 INTRODUCTION 123 TABLE 50 RWE SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 123 10.2 NORTH AMERICA 123 FIGURE 40 NORTH AMERICA: RWE SOLUTIONS MARKET SNAPSHOT 124 TABLE 51 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124 TABLE 52 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 125 TABLE 53 NORTH AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125 TABLE 54 NORTH AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125 TABLE 55 NORTH AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126 TABLE 56 NORTH AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 126 TABLE 57 NORTH AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 127 10.2.1 US 127 10.2.1.1 The US accounted for the largest share of the North American market 127 TABLE 58 US: MACROECONOMIC INDICATORS 128 TABLE 59 US: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 128 TABLE 60 US: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 128 TABLE 61 US: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 129 TABLE 62 US: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129 TABLE 63 US: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130 TABLE 64 US: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 130 10.2.2 CANADA 130 10.2.2.1 Growing number of clinical trials in Canada to drive market growth 130 TABLE 65 CANADA: MACROECONOMIC INDICATORS 131 TABLE 66 CANADA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 131 TABLE 67 CANADA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132 TABLE 68 CANADA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132 TABLE 69 CANADA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 132 TABLE 70 CANADA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 133 TABLE 71 CANADA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 133 10.3 EUROPE 133 TABLE 72 EUROPE: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134 TABLE 73 EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 135 TABLE 74 EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135 TABLE 75 EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135 TABLE 76 EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136 TABLE 77 EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 136 TABLE 78 EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 137 10.3.1 GERMANY 137 10.3.1.1 High pharmaceutical R&D spending in Germany to boost the market growth 137 TABLE 79 GERMANY: MACROECONOMIC INDICATORS 138 TABLE 80 GERMANY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 138 TABLE 81 GERMANY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139 TABLE 82 GERMANY: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139 TABLE 83 GERMANY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 140 TABLE 84 GERMANY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 140 TABLE 85 GERMANY: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 141 10.3.2 UK 141 10.3.2.1 The growing adoption of HTA in the UK supports market growth 141 TABLE 86 UK: MACROECONOMIC INDICATORS 142 TABLE 87 UK: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 142 TABLE 88 UK: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 142 TABLE 89 UK: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 143 TABLE 90 UK: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143 TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 144 TABLE 92 UK: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 144 10.3.3 FRANCE 144 10.3.3.1 High number of oncology clinical trials in France to drive market growth 144 TABLE 93 FRANCE: MACROECONOMIC INDICATORS 145 TABLE 94 FRANCE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 145 TABLE 95 FRANCE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146 TABLE 96 FRANCE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146 TABLE 97 FRANCE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 146 TABLE 98 FRANCE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147 TABLE 99 FRANCE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 147 10.3.4 ITALY 147 10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes 147 TABLE 100 ITALY: MACROECONOMIC INDICATORS 148 TABLE 101 ITALY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 149 TABLE 102 ITALY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149 TABLE 103 ITALY: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149 TABLE 104 ITALY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150 TABLE 105 ITALY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 150 TABLE 106 ITALY: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 151 10.3.5 SPAIN 151 10.3.5.1 Rising R&D expenditure to propel market growth in Spain 151 TABLE 107 SPAIN: MACROECONOMIC INDICATORS 152 TABLE 108 SPAIN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 152 TABLE 109 SPAIN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152 TABLE 110 SPAIN: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 153 TABLE 111 SPAIN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153 TABLE 112 SPAIN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154 TABLE 113 SPAIN: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 154 10.3.6 REST OF EUROPE 154 TABLE 114 REST OF EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 155 TABLE 115 REST OF EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 155 TABLE 116 REST OF EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 156 TABLE 117 REST OF EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 156 TABLE 118 REST OF EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 157 TABLE 119 REST OF EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 157 10.4 ASIA PACIFIC 158 FIGURE 41 ASIA PACIFIC: RWE SOLUTIONS MARKET SNAPSHOT 158 TABLE 120 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159 TABLE 121 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 159 TABLE 122 ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 159 TABLE 123 ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 160 TABLE 124 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160 TABLE 125 ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161 TABLE 126 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 161 10.4.1 JAPAN 161 10.4.1.1 Stringent regulatory scenario in Japan to restrain market growth 161 TABLE 127 JAPAN: MACROECONOMIC INDICATORS 162 TABLE 128 JAPAN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 163 TABLE 129 JAPAN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163 TABLE 130 JAPAN: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163 TABLE 131 JAPAN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 164 TABLE 132 JAPAN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164 TABLE 133 JAPAN: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 165 10.4.2 CHINA 165 10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth 165 TABLE 134 CHINA: MACROECONOMIC INDICATORS 166 TABLE 135 CHINA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 166 TABLE 136 CHINA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167 TABLE 137 CHINA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167 TABLE 138 CHINA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 167 TABLE 139 CHINA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168 TABLE 140 CHINA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 168 10.4.3 INDIA 168 10.4.3.1 Growing adoption of outcomes-based research among pharmaceutical and medical device manufacturers in India to drive market growth 168 TABLE 141 INDIA: MACROECONOMIC INDICATORS 169 TABLE 142 INDIA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 169 TABLE 143 INDIA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170 TABLE 144 INDIA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170 TABLE 145 INDIA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 170 TABLE 146 INDIA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171 TABLE 147 INDIA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 171 10.4.4 REST OF ASIA PACIFIC 171 TABLE 148 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 172 TABLE 149 REST OF ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172 TABLE 150 REST OF ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 173 TABLE 151 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 173 TABLE 152 REST OF ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 174 TABLE 153 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 174 10.5 LATIN AMERICA 174 10.5.1 INCREASED HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 174 TABLE 154 LATIN AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 175 TABLE 155 LATIN AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 175 TABLE 156 LATIN AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176 TABLE 157 LATIN AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176 TABLE 158 LATIN AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 177 TABLE 159 LATIN AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 177 10.6 MIDDLE EAST & AFRICA 177 10.6.1 GROWING AVAILABILITY OF HEALTHCARE FUNDING IN THE MIDDLE EAST OFFERS OPPORTUNITIES FOR MARKET GROWTH 177 TABLE 160 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 178 TABLE 161 MIDDLES EAST & AFRICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 178 TABLE 162 MIDDLES EAST & AFRICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 179 TABLE 163 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 179 TABLE 164 MIDDLES EAST & AFRICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180 TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 180 11 COMPETITIVE LANDSCAPE 181 11.1 OVERVIEW 181 11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN 181 TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE RWE SOLUTIONS MARKET 182 11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 184 FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN THE RWE SOLUTIONS MARKET 184 11.4 MARKET RANKING ANALYSIS 185 FIGURE 43 RWE SOLUTIONS MARKET RANKING, BY KEY PLAYER, 2021 185 11.5 COMPETITIVE BENCHMARKING 186 TABLE 167 RWE SOLUTIONS MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS 186 11.6 COMPANY FOOTPRINT 187 11.6.1 END-USER FOOTPRINT OF COMPANIES 187 11.6.2 PRODUCT FOOTPRINT OF COMPANIES 188 11.6.3 REGIONAL FOOTPRINT OF COMPANIES 189 11.7 COMPANY EVALUATION QUADRANT 190 11.7.1 STARS 191 11.7.2 EMERGING LEADERS 191 11.7.3 PERVASIVE PLAYERS 191 11.7.4 PARTICIPANTS 191 FIGURE 44 RWE SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021) 192 11.8 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 192 11.8.1 PROGRESSIVE COMPANIES 192 11.8.2 STARTING BLOCKS 193 11.8.3 RESPONSIVE COMPANIES 193 11.8.4 DYNAMIC COMPANIES 193 FIGURE 45 START-UP/SME EVALUATION QUADRANT (2021) 194 11.9 COMPETITIVE SCENARIO 194 11.9.1 FDA APPROVALS/SERVICE ENHANCEMENTS 194 TABLE 168 FDA APPROVALS/ENHANCEMENTS, 2019–2022 195 11.9.2 DEALS 195 TABLE 169 DEALS, 2019–2022 195 11.9.3 OTHER DEVELOPMENTS 197 TABLE 170 OTHER DEVELOPMENTS, 2019–2022 197 12 COMPANY PROFILES 198 12.1 KEY PLAYERS 198 (Business Overview, Products, Recent Developments, MnM View)* 12.1.1 IQVIA HOLDINGS INC. 198 TABLE 171 IQVIA HOLDINGS INC.: BUSINESS OVERVIEW 198 FIGURE 46 IQVIA HOLDINGS INC: COMPANY SNAPSHOT (2021) 199 12.1.2 IBM CORPORATION (IBM) 202 TABLE 172 IBM CORPORATION: BUSINESS OVERVIEW 202 FIGURE 47 IBM CORPORATION: COMPANY SNAPSHOT (2021) 203 12.1.3 OPTUM INC. (A SUBSIDIARY OF THE UNITED HEALTH GROUP, INC.) 205 TABLE 173 OPTUM INC.: BUSINESS OVERVIEW 205 FIGURE 48 OPTUM INC.: COMPANY SNAPSHOT (2021) 206 12.1.4 ICON PLC. 208 TABLE 174 ICON PLC.: BUSINESS OVERVIEW 208 FIGURE 49 ICON PLC.: COMPANY SNAPSHOT (2021) 209 12.1.5 SYNEOS HEALTH, INC. 211 TABLE 175 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 211 FIGURE 50 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021) 212 12.1.6 PAREXEL INTERNATIONAL CORPORATION 214 TABLE 176 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 214 12.1.7 THERMO FISHER SCIENTIFIC INC. 216 TABLE 177 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 216 FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 217 12.1.8 LABCORP HOLDINGS 219 TABLE 178 LABCORP HOLDINGS: BUSINESS OVERVIEW 219 FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021) 220 12.1.9 ORACLE CORPORATION 222 TABLE 179 ORACLE CORPORATION: BUSINESS OVERVIEW 222 FIGURE 53 ORACLE CORPORATION: COMPANY SNAPSHOT (2021) 223 12.1.10 ELEVANCE HEALTH 225 TABLE 180 ELEVANCE HEALTH: BUSINESS OVERVIEW 225 FIGURE 54 ELEVANCE HEALTH: COMPANY SNAPSHOT (2021) 226 12.1.11 SAS INSTITUTE 228 TABLE 181 SAS INSTITUTE: BUSINESS OVERVIEW 228 FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2021) 229 12.1.12 AETION INC. 231 TABLE 182 AETION INC.: BUSINESS OVERVIEW 231 12.1.13 TRINETX LLC 234 TABLE 183 TRINETX LLC: BUSINESS OVERVIEW 234 12.1.14 TRINITY LIFE SCIENCES 237 TABLE 184 TRINITY LIFE SCIENCES: BUSINESS OVERVIEW 237 12.1.15 PERKINELMER INC. 239 TABLE 185 PERKINELMER INC.: BUSINESS OVERVIEW 239 FIGURE 56 PERKINELMER INC.: COMPANY SNAPSHOT (2021) 240 12.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION 242 TABLE 186 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: BUSINESS OVERVIEW 242 FIGURE 57 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2021) 243 12.1.17 CLINIGEN 245 TABLE 187 CLINIGEN: BUSINESS OVERVIEW 245 FIGURE 58 CLINIGEN: COMPANY SNAPSHOT (2021) 245 12.1.18 CEGEDIM HEALTH DATA 247 TABLE 188 CEGEDIM HEALTH DATA: BUSINESS OVERVIEW 247 FIGURE 59 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2021) 247 12.1.19 VERANTOS INC. 249 TABLE 189 VERANTOS INC.: BUSINESS OVERVIEW 249 12.1.20 MEDPACE HOLDINGS INC. 251 TABLE 190 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 251 FIGURE 60 MEDPCE HOLDINGS INC.: COMPANY SNAPSHOT (2021) 252 *Details on Business Overview, Products, Recent Developments, MnM View might not be captured in case of unlisted companies. 12.2 OTHER PLAYERS 254 12.2.1 HEALTHVERITY INC. 254 12.2.2 DATAVANT 254 12.2.3 SYAPSE INC. 255 12.2.4 TEMPUS LABS INC. 255 12.2.5 FLATIRON HEALTH 256 13 APPENDIX 257 13.1 DISCUSSION GUIDE 257 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262 13.3 CUSTOMIZATION OPTIONS 264 13.4 RELATED REPORTS 264 13.5 AUTHOR DETAILS 265
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
MarketsandMarkets社の医療/ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(oncology)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |